TABLE 1.
Demographics
| Evaluable patients | Total cohort | PPQ+ | PPQ− |
|---|---|---|---|
| Total patients (n) | 67 | 40 | 27 |
| Age (y) | 66 (26–88) | 62 (26–86) | 72 (30–88)* |
| Sex | |||
| Male | 32 | 19 | 13 |
| Female | 35 | 21 | 14 |
| Time since diagnosis (mo) | 65 (5–213) (mean ± SD, 68 ± 50) | 74 (5–213) (mean ± SD, 75 ± 48) | 39 (7–185) (mean ± SD, 56 ± 53) |
| Time from start of PRRT to final assessment (mo) | 14 (1–31) | 24 (5–30) | 8 (0–31)* |
| NET origin | |||
| Bronchopulmonary | 3 (5%) | 1 | 2 |
| Typical carcinoids | 2 | 1 | 1 |
| Atypical carcinoids | 0 | ||
| Carcinoids not otherwise specified | 0 | ||
| High-grade (mixed adenocarcinoma and small cell lung carcinoma) | 1 | 1 | |
| Gastroenteropancreatic | 61 (91%) | 38 (95%) | 23 (85%) |
| Pancreas | 28 | 19 | 9 |
| Small intestine | 26 | 17 | 9 |
| Appendix | 1 | 0 | 1 |
| Rectum | 6 | 2 | 4 |
| Cancer of unknown primary | 1 | 0 | 1 |
| Renal | 2 | 1 | 1 |
| Gastroenteropancreatic NETs, tumor grade | |||
| 1 (Ki-67, 0%–2%) | 17 (28%) | 11 | 6 |
| 2 (Ki-67, 3%–20%) | 35 (57%) | 22 | 13 |
| 3 (Ki-67, >20%) | 8 (13%) | 4 | 4 |
| Nonspecified (well-differentiated) | 1 (2%) | 1 | 0 |
| Clinical stage IV at enrollment | 67(100%) | 40 (100%) | 27 (100%) |
| Liver | 58 | 32 | 26 |
| Lymph nodes | 51 | 27 | 24 |
| Bone | 37 | 18 | 19† |
| Peritoneum | 21 | 10 | 11 |
| Lung | 11 | 5 | 6 |
| Other sites (e.g., adrenal, pleura, pericardium) | 23 | 12 | 11 |
| Previous therapy | |||
| Surgery | 37 (55%) | 26 (65%) | 11 (41%) |
| Somatostatin analogs | 61 (91%) | 37 (93%) | 24 (89%) |
| Pharmacotherapy | 57 (85%) | 31 (77%) | 26 (96%) |
| Capecitabine and temozolomide | 21 | 12 | 9 |
| Chemotherapy (platinum/dacarbazine) | 12 | 8 | 4 |
| Everolimus | 15 | 7 | 8 |
| Sunitinib | 3 | 1 | 2 |
| Others (axitinib, cabozatinib, denosumab, zoledronic acid, and levatinib) | 6 | 3 | 3 |
| Other therapies | 38 (57%) | 21 (53%) | 17 (63%) |
| PRRT | 8‡ | 4 (3)§ | 4 (3)§ |
| Radiotherapy | 6 | 1 | 5 |
| Liver-directed therapies∥ | 24 | 16 | 8 |
*
P < 0.05 vs. PPQ+ (Mann–Whitney U test).
†
P < 0.05 (χ2).
‡
Six previously treated with JR-11.
§
Treated with JR-11.
∥
Including chemoembolization, radioembolization, and selective internal radiation therapy.
Qualitative data are number and percentage; continuous data are median and range.